Literature DB >> 10613359

Mature plasma cells as indicator of better prognosis in multiple myeloma. New methodology for the assessment of plasma cell morphology.

J E Goasguen1, M Zandecki, C Mathiot, J M Scheiff, M Bizet, B Ly-Sunnaram, B Grosbois, M Monconduit, J L Michaux, T Facon.   

Abstract

The relationship between plasmablastic cells and outcome in multiple myeloma (MM) has been established for nearly 15 years. But the assessment of these cells is not easy to perform and it allows the identification of only a small proportion of patients. We investigated the plasma cell morphology using a progressive evaluation of consecutive criteria: nucleolus, chromatin and nuclear-cellular ratio (N/C). The combination of these three items produces a subclassification where four cellular subtypes identify 93% of the plasma cells, and these subtypes are related to the outcome. The interest of this methodology is to be based on the mature plasma cells that are easier to identify than the plasmablastic cells. These new cell subtypes introduce a new classification for patients: Group 1 includes patients with at least 66% mature plasma cells (P000). Both Group 2 and 3 have less than 66% P000 and are separated by their degree of maturation (Proplasma I > or = Proplasma II + plasmablastic). The distinction of these three groups of patients is highly related to the prognosis (P < 10(-4)). These results have been confirmed on a second group of patients coming from a different institution. In conclusion, we propose a new methodology for the plasma cell evaluation in MM, that is based on the morphological criteria and that has the advantage of identifying an intermediate (30%) subgroup of patients with a prognostic significance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10613359     DOI: 10.1016/s0145-2126(99)00132-0

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  9 in total

1.  Anaplastic plasmacytoma of mouse--establishing parallels between subtypes of mouse and human plasma cell neoplasia.

Authors:  Daphne de Jong; Siegfried Janz
Journal:  J Pathol       Date:  2010-07       Impact factor: 7.996

2.  Development and validation of an immune-related gene pairs signature in colorectal cancer.

Authors:  Jianping Wu; Ying Zhao; Juanwen Zhang; Qianxia Wu; Weilin Wang
Journal:  Oncoimmunology       Date:  2019-04-15       Impact factor: 8.110

3.  A proposed index of diffuse bone marrow [18F]-FDG uptake and PET skeletal patterns correlate with myeloma prognostic markers, plasma cell morphology, and response to therapy.

Authors:  A Paschali; E Panagiotidis; T Triantafyllou; V Palaska; K Tsirou; E Verrou; E Υiannaki; D Markala; A Papanikolaou; A Pouli; P Konstantinidou; V Chatzipavlidou; E Terpos; E Katodritou
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-10-25       Impact factor: 9.236

4.  Clinical, immunophenotypic, and genetic characterization of small lymphocyte-like plasma cell myeloma: a potential mimic of mature B-cell lymphoma.

Authors:  Amy Heerema-McKenney; James Waldron; Steven Hughes; Fenghuang Zhan; Jeffery Sawyer; Bart Barlogie; John D Shaughnessy
Journal:  Am J Clin Pathol       Date:  2010-02       Impact factor: 2.493

5.  Fractal characteristics of May-Grünwald-Giemsa stained chromatin are independent prognostic factors for survival in multiple myeloma.

Authors:  Daniela P Ferro; Monica A Falconi; Randall L Adam; Manoela M Ortega; Carmen P Lima; Carmino A de Souza; Irene Lorand-Metze; Konradin Metze
Journal:  PLoS One       Date:  2011-06-16       Impact factor: 3.240

6.  DEPTOR maintains plasma cell differentiation and favorably affects prognosis in multiple myeloma.

Authors:  Dalia Quwaider; Luis A Corchete; Irena Misiewicz-Krzeminska; María E Sarasquete; José J Pérez; Patryk Krzeminski; Noemí Puig; María Victoria Mateos; Ramón García-Sanz; Ana B Herrero; Norma C Gutiérrez
Journal:  J Hematol Oncol       Date:  2017-04-18       Impact factor: 17.388

Review 7.  Cytology and clinical features of myelomatous pleural effusion: Three case reports and a review of the literature.

Authors:  Hong Chen; Pengfei Li; Yan Xie; Mulan Jin
Journal:  Diagn Cytopathol       Date:  2018-02-05       Impact factor: 1.582

8.  The morphology of myeloma cells changes with progression of the disease.

Authors:  Jarosław Wajs; Waldemar Sawicki
Journal:  Contemp Oncol (Pozn)       Date:  2013-06-28

9.  Plasmablastic myeloma presenting as rapidly progressive renal failure in a young adult.

Authors:  M Srija; P P Zachariah; V N Unni; A Mathew; R Rajesh; G Kurian; S Neeraj; N V Seethalekshmi; N V Smitha
Journal:  Indian J Nephrol       Date:  2014-01
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.